Journal
ALZHEIMERS & DEMENTIA
Volume 12, Issue 11, Pages 1159-1166Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2016.05.003
Keywords
Synaptic function; Neurogranin; APOE epsilon 4; Alzheimer's disease; APOE; Mild cognitive impairment
Categories
Funding
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
- DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Canadian Institutes of Health Research
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Araclon Biotech
- BioClinica, Inc.
- Biogen
- Bristol-Myers Squibb Company
- CereSpir, Inc.
- Eisai
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- EuroImmun
- F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.
- Fujirebio
- GE Healthcare
- IXICO Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC
- Johnson & Johnson Pharmaceutical Research & Development LLC
- Lumosity
- Lundbeck
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC
- NeuroRx Research
- Neurotrack Technologies
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Piramal Imaging
- Servier
- Takeda Pharmaceutical Company
- Transition Therapeutics
Ask authors/readers for more resources
Introduction: Pathogenesis of Alzheimer's disease (AD) in apolipoprotein E epsilon 4 (APOE epsilon 4) carriers remains unclear. We hypothesize that APOE isoforms have differential effects on synaptic function. Methods: We compared levels of CSF neurogranin (Ng) between APOE epsilon 4 carriers and noncarriers in 399 subjects with normal cognition, mild cognitive impairment (MCI), and AD. We examined associations between Ng levels and age, education, gender, CSF-A beta 42, and tau protein. Results: Neurogranin levels were significantly higher in APOE epsilon 4 carriers compared to APOE epsilon 4 noncarriers with MCI. Levels of Ng between the APOE epsilon 4 carriers and APOE 64 noncarriers with AD did not differ. Ng levels were correlated with MMSE and levels of tau and A beta 42. Discussion: Significantly higher CSF Ng levels in APOE epsilon 4 carriers with MCI may reflect synaptic injury underlying early cognitive impairment. Neurogranin may be an early biomarker of AD and important for disease diagnosis and timing of intervention in APOE epsilon 4 carriers. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available